Tag: major depressive disorder
October 31, 2018
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial
ACADIA Pharmaceuticals (Nasdaq:ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD)... June 12, 2018
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meetin
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced... May 7, 2018
Landmark Study Shows GeneSight Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder
Assurex Health, a wholly-owned subsidiary of Myriad Genetics (NASDAQ:MYGN), today announced that results from a large, well-controlled pharmacogenomics study in...
April 30, 2018
Key Stock Catalysts in the FDA Drug Application Process
Pharmaceutical and biotech companies in the US must follow a standard process to advance a new drug candidate through nonclinical...
April 26, 2018
Axsome Therapeutics Announces Interim Analysis of STRIDE-1 Trial
Shares of Axsome increased nearly 20 percent after the announcement, but evened out to an overall 13.21-percent increase to $3. April 9, 2018
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Minerva Neurosciences (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders,... April 5, 2018